Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 29 | 2022 | 98 | 4.960 |
Why?
|
| Antidepressive Agents | 26 | 2023 | 93 | 3.390 |
Why?
|
| Depressive Disorder | 30 | 2007 | 167 | 2.880 |
Why?
|
| Bipolar Disorder | 14 | 2017 | 99 | 2.160 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 6 | 2023 | 9 | 2.000 |
Why?
|
| Antidepressive Agents, Second-Generation | 13 | 2010 | 26 | 1.360 |
Why?
|
| Psychiatric Status Rating Scales | 26 | 2020 | 304 | 1.160 |
Why?
|
| Ketamine | 2 | 2023 | 25 | 0.990 |
Why?
|
| Antipsychotic Agents | 9 | 2016 | 57 | 0.950 |
Why?
|
| Fluoxetine | 15 | 2009 | 30 | 0.950 |
Why?
|
| Secondary Prevention | 16 | 2020 | 52 | 0.870 |
Why?
|
| Triazoles | 7 | 2003 | 27 | 0.850 |
Why?
|
| Double-Blind Method | 29 | 2020 | 398 | 0.840 |
Why?
|
| Vagus Nerve Stimulation | 2 | 2022 | 7 | 0.760 |
Why?
|
| Tetrahydrofolates | 3 | 2016 | 3 | 0.760 |
Why?
|
| Valproic Acid | 5 | 2008 | 11 | 0.740 |
Why?
|
| Treatment Outcome | 34 | 2022 | 3292 | 0.730 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2003 | 33 | 0.720 |
Why?
|
| Depression | 7 | 2022 | 407 | 0.710 |
Why?
|
| Humans | 78 | 2023 | 25967 | 0.680 |
Why?
|
| Cyclohexanols | 9 | 2010 | 18 | 0.630 |
Why?
|
| Drug Therapy, Combination | 15 | 2019 | 170 | 0.610 |
Why?
|
| Adult | 45 | 2019 | 7351 | 0.600 |
Why?
|
| Suicidal Ideation | 1 | 2017 | 5 | 0.570 |
Why?
|
| Male | 56 | 2020 | 13984 | 0.560 |
Why?
|
| Sexual Dysfunctions, Psychological | 5 | 2005 | 10 | 0.560 |
Why?
|
| Female | 54 | 2020 | 14351 | 0.540 |
Why?
|
| Middle Aged | 36 | 2020 | 8508 | 0.520 |
Why?
|
| Piperazines | 11 | 2015 | 76 | 0.500 |
Why?
|
| Electroconvulsive Therapy | 3 | 2017 | 16 | 0.460 |
Why?
|
| Folic Acid | 2 | 2016 | 13 | 0.420 |
Why?
|
| Anxiety Disorders | 4 | 2002 | 157 | 0.400 |
Why?
|
| Drug Administration Schedule | 15 | 2007 | 156 | 0.380 |
Why?
|
| Acetamides | 1 | 2010 | 2 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 315 | 0.340 |
Why?
|
| Sexual Behavior | 2 | 2002 | 50 | 0.330 |
Why?
|
| Pirenzepine | 3 | 2003 | 5 | 0.320 |
Why?
|
| Adolescent | 13 | 2015 | 2062 | 0.300 |
Why?
|
| Acute Disease | 7 | 2013 | 189 | 0.280 |
Why?
|
| Personality Inventory | 5 | 2012 | 66 | 0.280 |
Why?
|
| Antimanic Agents | 1 | 2006 | 5 | 0.280 |
Why?
|
| Social Adjustment | 2 | 2010 | 24 | 0.260 |
Why?
|
| Administration, Intranasal | 2 | 2023 | 25 | 0.250 |
Why?
|
| Aged | 17 | 2016 | 8704 | 0.250 |
Why?
|
| Sertraline | 5 | 2006 | 23 | 0.250 |
Why?
|
| Chronic Disease | 6 | 2017 | 416 | 0.240 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 1066 | 0.240 |
Why?
|
| Remission Induction | 5 | 2020 | 88 | 0.230 |
Why?
|
| Venlafaxine Hydrochloride | 9 | 2010 | 17 | 0.230 |
Why?
|
| Obsessive-Compulsive Disorder | 4 | 2006 | 18 | 0.230 |
Why?
|
| Prospective Studies | 4 | 2017 | 1646 | 0.220 |
Why?
|
| Placebos | 7 | 2006 | 66 | 0.220 |
Why?
|
| Obesity | 3 | 2015 | 276 | 0.220 |
Why?
|
| Recurrence | 5 | 2016 | 306 | 0.210 |
Why?
|
| Ambulatory Care | 7 | 2008 | 68 | 0.200 |
Why?
|
| Young Adult | 5 | 2016 | 1848 | 0.200 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 1710 | 0.200 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 277 | 0.180 |
Why?
|
| Quality of Life | 5 | 2010 | 609 | 0.180 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 2 | 0.170 |
Why?
|
| Pyrrolidines | 1 | 2020 | 11 | 0.170 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 10 | 0.170 |
Why?
|
| Benzamides | 1 | 2020 | 15 | 0.170 |
Why?
|
| Patient Compliance | 5 | 2007 | 145 | 0.160 |
Why?
|
| Psychotic Disorders | 2 | 2001 | 37 | 0.150 |
Why?
|
| Long-Term Care | 2 | 2016 | 55 | 0.150 |
Why?
|
| Thiazoles | 2 | 2012 | 18 | 0.150 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2004 | 15 | 0.150 |
Why?
|
| Severity of Illness Index | 6 | 2007 | 929 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2015 | 99 | 0.140 |
Why?
|
| Phenethylamines | 1 | 2016 | 1 | 0.140 |
Why?
|
| Comorbidity | 6 | 2015 | 466 | 0.140 |
Why?
|
| Pyridines | 1 | 2016 | 36 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 304 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 171 | 0.130 |
Why?
|
| Glutamates | 1 | 2015 | 9 | 0.130 |
Why?
|
| Psychometrics | 5 | 2012 | 225 | 0.130 |
Why?
|
| Serotonin | 2 | 1997 | 24 | 0.130 |
Why?
|
| Dizziness | 4 | 2007 | 18 | 0.130 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2007 | 4 | 0.120 |
Why?
|
| Hypericum | 2 | 2005 | 3 | 0.120 |
Why?
|
| Paroxetine | 4 | 2007 | 14 | 0.120 |
Why?
|
| Phytotherapy | 2 | 2005 | 11 | 0.120 |
Why?
|
| Sulfides | 1 | 2015 | 10 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 37 | 0.120 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2014 | 1 | 0.120 |
Why?
|
| Aldehydes | 1 | 2014 | 2 | 0.120 |
Why?
|
| S-Adenosylmethionine | 1 | 2014 | 5 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2019 | 100 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2000 | 50 | 0.110 |
Why?
|
| Vagus Nerve | 2 | 2022 | 13 | 0.110 |
Why?
|
| Nausea | 3 | 1999 | 23 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 342 | 0.110 |
Why?
|
| Inflammation | 1 | 2015 | 264 | 0.110 |
Why?
|
| Anticonvulsants | 2 | 2003 | 54 | 0.100 |
Why?
|
| Hypertension | 2 | 2007 | 217 | 0.100 |
Why?
|
| Tranylcypromine | 1 | 1991 | 2 | 0.100 |
Why?
|
| Prevalence | 1 | 2013 | 433 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2005 | 670 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 52 | 0.090 |
Why?
|
| Headache | 3 | 2007 | 30 | 0.090 |
Why?
|
| Patient Education as Topic | 3 | 2003 | 139 | 0.090 |
Why?
|
| Orgasm | 1 | 1991 | 10 | 0.090 |
Why?
|
| Fever | 1 | 1991 | 34 | 0.090 |
Why?
|
| Attitude to Health | 2 | 2002 | 92 | 0.090 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2015 | 9 | 0.090 |
Why?
|
| Patient Selection | 1 | 2011 | 193 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2010 | 76 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2010 | 46 | 0.090 |
Why?
|
| Tachyphylaxis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Benzodiazepines | 3 | 2003 | 45 | 0.080 |
Why?
|
| Delayed-Action Preparations | 4 | 2010 | 27 | 0.080 |
Why?
|
| Sleep Stages | 2 | 1999 | 20 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2015 | 986 | 0.070 |
Why?
|
| 1-Naphthylamine | 2 | 1997 | 4 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 10 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 30 | 0.070 |
Why?
|
| Half-Life | 2 | 1997 | 9 | 0.070 |
Why?
|
| Serotonin Antagonists | 2 | 2001 | 8 | 0.070 |
Why?
|
| Syndrome | 2 | 1997 | 73 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2010 | 253 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 40 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2004 | 6 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2007 | 70 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 77 | 0.060 |
Why?
|
| Weight Gain | 3 | 2001 | 60 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 41 | 0.060 |
Why?
|
| Sex Factors | 2 | 2005 | 442 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2007 | 3290 | 0.060 |
Why?
|
| Thiophenes | 1 | 2004 | 10 | 0.060 |
Why?
|
| Morpholines | 1 | 2003 | 11 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2003 | 35 | 0.050 |
Why?
|
| Health Status | 3 | 2003 | 211 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2002 | 7 | 0.050 |
Why?
|
| Body Weight | 2 | 2002 | 121 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2003 | 51 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2002 | 40 | 0.050 |
Why?
|
| Biomarkers | 2 | 2015 | 548 | 0.050 |
Why?
|
| Drug Interactions | 2 | 1991 | 35 | 0.050 |
Why?
|
| Mianserin | 1 | 2001 | 8 | 0.050 |
Why?
|
| Buspirone | 1 | 2001 | 4 | 0.050 |
Why?
|
| Bupropion | 1 | 2001 | 6 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 11 | 0.050 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 10 | 0.050 |
Why?
|
| Sulfones | 1 | 2001 | 20 | 0.050 |
Why?
|
| Sexuality | 1 | 2001 | 14 | 0.050 |
Why?
|
| Telephone | 1 | 2000 | 24 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2001 | 35 | 0.040 |
Why?
|
| Self Disclosure | 1 | 2000 | 4 | 0.040 |
Why?
|
| Purines | 1 | 2001 | 42 | 0.040 |
Why?
|
| Asthenia | 1 | 2000 | 1 | 0.040 |
Why?
|
| Desipramine | 1 | 2000 | 3 | 0.040 |
Why?
|
| Feeding and Eating Disorders | 1 | 2000 | 10 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 288 | 0.040 |
Why?
|
| Nasal Sprays | 1 | 2019 | 3 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2000 | 81 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 485 | 0.040 |
Why?
|
| Anxiety | 1 | 1999 | 135 | 0.040 |
Why?
|
| Drug Synergism | 2 | 1995 | 38 | 0.040 |
Why?
|
| Prognosis | 1 | 2000 | 749 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1997 | 2 | 0.040 |
Why?
|
| MEDLINE | 1 | 1997 | 4 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 1997 | 11 | 0.040 |
Why?
|
| Time Factors | 3 | 2010 | 1361 | 0.040 |
Why?
|
| Abbreviations as Topic | 1 | 1997 | 1 | 0.040 |
Why?
|
| Paresthesia | 1 | 1997 | 2 | 0.040 |
Why?
|
| Receptors, Serotonin | 1 | 1997 | 12 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1997 | 11 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1997 | 15 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 16 | 0.030 |
Why?
|
| Life Change Events | 1 | 1997 | 31 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 30 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1997 | 26 | 0.030 |
Why?
|
| Quetiapine Fumarate | 1 | 2016 | 2 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1997 | 92 | 0.030 |
Why?
|
| Triazines | 1 | 2016 | 12 | 0.030 |
Why?
|
| Imipramine | 1 | 1996 | 10 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1997 | 215 | 0.030 |
Why?
|
| Community Mental Health Services | 1 | 1996 | 11 | 0.030 |
Why?
|
| Family Practice | 1 | 1996 | 15 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2006 | 42 | 0.030 |
Why?
|
| Adiponectin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Infant | 1 | 1997 | 493 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 19 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 1995 | 8 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1997 | 126 | 0.030 |
Why?
|
| Primary Health Care | 1 | 1997 | 90 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 1997 | 538 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 72 | 0.030 |
Why?
|
| Plant Extracts | 2 | 2005 | 12 | 0.030 |
Why?
|
| Affect | 1 | 1995 | 53 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1995 | 30 | 0.030 |
Why?
|
| Phobic Disorders | 1 | 1995 | 64 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 186 | 0.030 |
Why?
|
| Incidence | 1 | 1997 | 706 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1995 | 129 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1993 | 6 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 1995 | 94 | 0.030 |
Why?
|
| Lithium | 1 | 1993 | 17 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 335 | 0.030 |
Why?
|
| Child | 1 | 1997 | 1226 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 70 | 0.030 |
Why?
|
| Amitriptyline | 1 | 1991 | 3 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1991 | 5 | 0.020 |
Why?
|
| Pemoline | 1 | 1991 | 1 | 0.020 |
Why?
|
| Dextroamphetamine | 1 | 1991 | 2 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1991 | 17 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 1991 | 25 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1223 | 0.020 |
Why?
|
| Risk Factors | 1 | 1997 | 2240 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1990 | 6 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 105 | 0.020 |
Why?
|
| Hospitalization | 1 | 1991 | 290 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 161 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2007 | 20 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2007 | 22 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 34 | 0.020 |
Why?
|
| Outpatients | 1 | 2007 | 53 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 132 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1338 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2005 | 20 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2005 | 25 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 184 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2007 | 211 | 0.010 |
Why?
|
| United States | 1 | 2010 | 1972 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2003 | 3 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 546 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 59 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 8 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 235 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 69 | 0.010 |
Why?
|
| Suicide | 1 | 2002 | 10 | 0.010 |
Why?
|
| Priapism | 1 | 2002 | 11 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 63 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2001 | 26 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2001 | 7 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2001 | 55 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2001 | 25 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 148 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2001 | 66 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 298 | 0.010 |
Why?
|
| Appetite | 1 | 1999 | 4 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 742 | 0.010 |
Why?
|
| Weight Loss | 1 | 1999 | 120 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1999 | 411 | 0.010 |
Why?
|